A 22-year-old man was referred with decreased visual acuity of 4 years duration and bilateral ‘positive’ scotomata. Past medical and ocular history was unremarkable. Visual acuity (VA) was 0.30 logMAR ...

Please provide your email address to receive an email when new articles are posted on . Beacon Therapeutics launches with an X-linked retinitis pigmentosa therapy in phase 2 trials. Preclinical assets ...

image: With a $2.5 million grant from the National Eye Institute, a team of biomedical researchers (who just happen to be married for 44 years) at the University of Houston is tackling the link ...

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Cone Rod Dystrophy Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been ...

The lead asset of Applied Genetic Technologies Corp. has been spun into Beacon Therapeutics Ltd., which launches with $120.9 million to run a phase II/III pivotal trial of AGTC-501 in X-linked ...